A Study to Describe the Safety and Effectiveness of Venetoclax in Acute Myeloid Leukemia (AML) Patients (REVIVE Study)
Call us @: 844 663-3742
Study Details
Medical Condition
Study Phase
Intervention Type
Date
Participation Requirements
Gender
Age
Healthy Volunteers
Inclusion Criteria
Exclusion Criteria
Have a question?
You can ask us questions via online form or phone call.
Call us @: 844 663-3742
| Location | Status | Site Contact Details |
|---|---|---|
Location HaEmek Medical Center, Afula, H_efa, 1834111 | Status Active, Not Recruiting | |
Location Rambam Health Care Campus, Haifa, H_efa, 3109601 | Status Active, Not Recruiting | |
Location Bnai Zion Medical Center, Haifa, H_efa, 3339419 | Status Active, Not Recruiting | |
Location Soroka University Medical Center, Be'er Sheva, HaDarom, 8443901 | Status Active, Not Recruiting | |
Location Meir Medical Center, Kfar Saba, HaMerkaz, 4428164 | Status Recruiting | |
Location Assuta Tel Aviv Medical Center, Tel Aviv, HaMerkaz, 6971028 | Status Active, Not Recruiting | |
Location ZIV Medical Center, Safed, HaTsafon, 13100 | Status Completed | |
Location The Chaim Sheba Medical Center, Ramat Gan, Tel-Aviv, 5265601 | Status Active, Not Recruiting | |
Location Tel Aviv Sourasky Medical Center, Tel Aviv, Tel-Aviv, 6423906 | Status Active, Not Recruiting | |
Location Shaare Zedek Medical Center, Jerusalem, Yerushalayim, 91031 | Status Active, Not Recruiting | |
Location Hadassah, Jerusalem, Yerushalayim, 91120 | Status Active, Not Recruiting | |
Location Rabin Medical Center, Haifa, 4941492 | Status Active, Not Recruiting |
This study will describe the safety and effectiveness of venetoclax in AML patients in routine clinical practice in Israel. The decision to treat with venetoclax is made by the physician prior to any decision regarding participation in this study.
Overall Survival
Time Frame: Time from treatment to death from any cause, up to approximately 30 months
Percentage of participants achieving composite complete remission (CR or CRi)
Time Frame: Approximately 30 months
Time to transfusion independence
Time Frame: Up to 30 months
Change in patient reported outcomes for the Euro Quality of Life 5 Dimensions 5 Levels Questionnaire (EQ-5D-5L)
Time Frame: Week 0 to approximately 30 months
Percentage of participants treated with venetoclax as compared to participants treated with other approved biologics
Time Frame: Up to approximately 30 months
Change in patient reported outcomes for the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire CORE (EORTC QLQ-C30)
Time Frame: Week 0 to approximately 30 months
Percentage of participants achieving transfusion independence
Time Frame: Up to 30 months
Interventions:
- Not Available
Enrollment:
100
Additional Information
Watch a video to learn more about what you may experience as a clinical trial volunteer: /resources/what-happens-in-a-clinical-trial
Take a virtual reality screening visit tour to an example of a clinical trial site: /resources/screening-visit-virtual-tour
Use a questionnaire tool to think through questions to ask yourself about participating in a clinical trial and print out your responses to discuss with your partners in your health journey: /resource-information-clinical-trial-community/decision-counselor